SCHEMBL21754307

SCHEMBL21754307

Clc1nc(NCCc2c[nH]c3ccccc23)c2ccsc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ SLC2A1 P11166 1/20 0.51
▸ RAD52 P43351 1/20 0.51
▸ HTT P42858 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ GBA1 P04062 1/20 0.48
▸ HTR2A P28223 5/20 0.47
▸ HTR1A P08908 4/20 0.47
▸ DRD2 P14416 3/20 0.47
▸ HTR7 P34969 3/20 0.47
▸ HTR6 P50406 3/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27318656 0.83 HTT (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL30867135 0.83 HTT (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL30867137 0.83 HTT (0.49) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL20267087 0.82 KMT2A (0.67) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL29244533 0.78 KMT2A (0.54) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL20557935 0.78 GBA1 (0.55) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL20542051 0.78 KMT2A (0.48) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL28046116 0.77 HTR2A (0.64) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL29244496 0.77 KMT2A (0.55) KMT2APOLBSLC2A1RAD52HTT
SCHEMBL30278225 0.77 KMT2A (0.55) KMT2APOLBSLC2A1RAD52HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KMT2A 622/4885POLB 4041/4885SLC2A1 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback